JP6270823B2 - ステロール誘導体、及び形質転換した星状膠細胞に関係する疾患を治療するため、または悪性血液疾患を治療するためのその使用 - Google Patents
ステロール誘導体、及び形質転換した星状膠細胞に関係する疾患を治療するため、または悪性血液疾患を治療するためのその使用 Download PDFInfo
- Publication number
- JP6270823B2 JP6270823B2 JP2015510925A JP2015510925A JP6270823B2 JP 6270823 B2 JP6270823 B2 JP 6270823B2 JP 2015510925 A JP2015510925 A JP 2015510925A JP 2015510925 A JP2015510925 A JP 2015510925A JP 6270823 B2 JP6270823 B2 JP 6270823B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- formula
- cells
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305518.8A EP2662382B1 (fr) | 2012-05-10 | 2012-05-10 | Dérivés de stérol, leur procédé de préparation, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement du glioblastome multiple |
| EP12305518.8 | 2012-05-10 | ||
| US201261656151P | 2012-06-06 | 2012-06-06 | |
| US61/656,151 | 2012-06-06 | ||
| PCT/IB2013/053669 WO2013168096A1 (en) | 2012-05-10 | 2013-05-07 | Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520146A JP2015520146A (ja) | 2015-07-16 |
| JP2015520146A5 JP2015520146A5 (enExample) | 2016-06-30 |
| JP6270823B2 true JP6270823B2 (ja) | 2018-01-31 |
Family
ID=46149353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510925A Active JP6270823B2 (ja) | 2012-05-10 | 2013-05-07 | ステロール誘導体、及び形質転換した星状膠細胞に関係する疾患を治療するため、または悪性血液疾患を治療するためのその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10800806B2 (enExample) |
| EP (2) | EP2662382B1 (enExample) |
| JP (1) | JP6270823B2 (enExample) |
| KR (1) | KR102160316B1 (enExample) |
| CN (1) | CN104302655B (enExample) |
| BR (1) | BR112014026948B1 (enExample) |
| CA (1) | CA2871714C (enExample) |
| CY (2) | CY1117723T1 (enExample) |
| DK (2) | DK2662382T3 (enExample) |
| ES (2) | ES2580331T3 (enExample) |
| HR (2) | HRP20180345T1 (enExample) |
| HU (2) | HUE029243T2 (enExample) |
| IN (1) | IN2014DN09437A (enExample) |
| LT (1) | LT2847204T (enExample) |
| ME (1) | ME02436B (enExample) |
| PL (2) | PL2662382T3 (enExample) |
| PT (2) | PT2662382T (enExample) |
| RS (2) | RS54926B1 (enExample) |
| RU (1) | RU2627710C2 (enExample) |
| SI (2) | SI2662382T1 (enExample) |
| SM (2) | SMT201800147T1 (enExample) |
| TR (1) | TR201802700T4 (enExample) |
| WO (1) | WO2013168096A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021524490A (ja) * | 2018-07-11 | 2021-09-13 | ベータ・イノブ | ７ベータ−ヒドロキシコレステロール及び脂質ビヒクルを含む組成物、並びに腫瘍性病態の処置におけるその使用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3013048A1 (fr) * | 2013-11-12 | 2015-05-15 | Beta Innov | Derive de sterol, son procede de preparation, composition pharmaceutique le contenant et son utilisation pour le traitement du glioblastome multiforme |
| KR102689231B1 (ko) * | 2021-05-18 | 2024-07-30 | 연세대학교 산학협력단 | 암의 예방, 개선 또는 치료용 조성물 |
| KR102748745B1 (ko) * | 2021-05-18 | 2025-01-03 | 연세대학교 산학협력단 | 암의 예방, 개선 또는 치료용 조성물 |
| WO2024030660A2 (en) * | 2022-08-04 | 2024-02-08 | University Of Massachusetts | Cholesterol-modified hyaluronic acids |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9602100D0 (sv) * | 1996-05-30 | 1996-05-30 | Magnus Axelson | New pharmaceuticals |
| JP2006503840A (ja) * | 2002-09-25 | 2006-02-02 | フォーブス メディ−テック インコーポレーテッド | ステロール及び／又はスタノール及び抗炎症剤の特定の種類を含有する新規構造体及び組成物、並びに、心血管疾患、その根底にある高脂血症を含む病気、及び原因又は症状の一部として炎症を有する他の障害の治療又は予防におけるそれらの使用 |
-
2012
- 2012-05-10 EP EP12305518.8A patent/EP2662382B1/fr active Active
- 2012-05-10 DK DK12305518.8T patent/DK2662382T3/en active
- 2012-05-10 ME MEP-2016-134A patent/ME02436B/me unknown
- 2012-05-10 HU HUE12305518A patent/HUE029243T2/en unknown
- 2012-05-10 RS RS20160499A patent/RS54926B1/sr unknown
- 2012-05-10 ES ES12305518.8T patent/ES2580331T3/es active Active
- 2012-05-10 PT PT123055188T patent/PT2662382T/pt unknown
- 2012-05-10 SI SI201230585A patent/SI2662382T1/sl unknown
- 2012-05-10 PL PL12305518.8T patent/PL2662382T3/pl unknown
-
2013
- 2013-05-07 LT LTEP13729470.8T patent/LT2847204T/lt unknown
- 2013-05-07 SI SI201330962T patent/SI2847204T1/en unknown
- 2013-05-07 RU RU2014149705A patent/RU2627710C2/ru active
- 2013-05-07 CN CN201380023824.4A patent/CN104302655B/zh active Active
- 2013-05-07 TR TR2018/02700T patent/TR201802700T4/tr unknown
- 2013-05-07 HR HRP20180345TT patent/HRP20180345T1/hr unknown
- 2013-05-07 CA CA2871714A patent/CA2871714C/en active Active
- 2013-05-07 JP JP2015510925A patent/JP6270823B2/ja active Active
- 2013-05-07 US US14/399,336 patent/US10800806B2/en active Active
- 2013-05-07 WO PCT/IB2013/053669 patent/WO2013168096A1/en not_active Ceased
- 2013-05-07 PT PT137294708T patent/PT2847204T/pt unknown
- 2013-05-07 ES ES13729470.8T patent/ES2662123T3/es active Active
- 2013-05-07 KR KR1020147034290A patent/KR102160316B1/ko active Active
- 2013-05-07 HU HUE13729470A patent/HUE037004T2/hu unknown
- 2013-05-07 PL PL13729470T patent/PL2847204T3/pl unknown
- 2013-05-07 IN IN9437DEN2014 patent/IN2014DN09437A/en unknown
- 2013-05-07 BR BR112014026948-3A patent/BR112014026948B1/pt active IP Right Grant
- 2013-05-07 RS RS20180237A patent/RS57065B1/sr unknown
- 2013-05-07 EP EP13729470.8A patent/EP2847204B1/en active Active
- 2013-05-07 SM SM20180147T patent/SMT201800147T1/it unknown
- 2013-05-07 DK DK13729470.8T patent/DK2847204T3/en active
-
2016
- 2016-06-07 HR HRP20160624TT patent/HRP20160624T1/hr unknown
- 2016-07-05 SM SM201600215T patent/SMT201600215B/it unknown
- 2016-07-05 CY CY20161100621T patent/CY1117723T1/el unknown
-
2018
- 2018-03-13 CY CY20181100306T patent/CY1120395T1/el unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021524490A (ja) * | 2018-07-11 | 2021-09-13 | ベータ・イノブ | ７ベータ−ヒドロキシコレステロール及び脂質ビヒクルを含む組成物、並びに腫瘍性病態の処置におけるその使用 |
| JP7547312B2 (ja) | 2018-07-11 | 2024-09-09 | ベータ・イノブ | ７ベータ－ヒドロキシコレステロール及び脂質ビヒクルを含む組成物、並びに腫瘍性病態の処置におけるその使用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6270823B2 (ja) | ステロール誘導体、及び形質転換した星状膠細胞に関係する疾患を治療するため、または悪性血液疾患を治療するためのその使用 | |
| CN103417532B (zh) | 倍半萜内酯类化合物及其衍生物在制备药物中的用途 | |
| JP2022501348A (ja) | ステロール類似体及びその使用 | |
| US8299125B2 (en) | Water-soluble triterpenephenol compounds having antitumor activity and the preparation thereof | |
| Sun et al. | A novel oral prodrug-targeting transporter MCT 1: 5-fluorouracil-dicarboxylate monoester conjugates | |
| JP5542930B2 (ja) | ステロール誘導体、並びにそれらの合成及び使用 | |
| JP2002504509A (ja) | タンパク質ファルネシル転移酵素阻害剤 | |
| CN112979541B (zh) | 一种基于n-(3-羟基吡啶-2-羰基)甘氨酸的抗肿瘤药物增敏剂及其应用 | |
| RU2440998C1 (ru) | Производные 4-арилкумаринов и противоопухолевое лекарственное средство на их основе | |
| CN110357844B (zh) | 一种淫羊藿苷元衍生物及其制备方法和用途 | |
| WO2017156959A1 (zh) | 一种小分子肺靶向药物 | |
| HK1207385B (en) | Sterol derivatives and use thereof for treating diseases involving transformed astrocyte cells or for treating malignant haemopathies | |
| CN104892627A (zh) | 氨基酸二氢青蒿素衍生物及其制备方法与应用 | |
| CN110357845B (en) | Icariin derivative and preparation method and application thereof | |
| HK1191654B (en) | Sterol derivatives, method for preparing same, pharmaceutical compositions containing same and use thereof for the treatment of multiple glioblastomas | |
| JP5670858B2 (ja) | サイトゾルのホスホリパーゼのモジュレーターとしてのグリセロホスホイノシトール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160502 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160502 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170509 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170714 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171108 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171212 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171226 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6270823 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |